Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins

Journal of Endocrinology

Volumn 160, Issue 2, 1999, Pages 223-229

  Nickerson, T ^a   Huynh, H ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SEOCALCITOL; SOMATOMEDIN BINDING PROTEIN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; DRUG EFFECT; GROWTH INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS REGULATION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, NORTHERN; CALCITRIOL; GENE EXPRESSION; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; PROSTATE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 0033049435     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1600223     Document Type: Article

References (39)

1. Baker AR, McDonell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J & O'Malley BW 1988 Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proceedings of the National Academy of Sciences of the USA 85 3294-3298.
2. Baserga R 1995 The insulin-like growth factor-I receptor: a key to tumor growth? Cancer Research 55 249-252.
3. 1. Endocrinology 138 1491-1497.
4. Campbell MJ & Koeffler HP 1997 Toward therapeutic intervention of cancer by vitamin D compounds. Journal of the National Cancer Institute 89 182-185.
5. Chan JM, Stampfer MK, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH & Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 563-566.
6. Clemmons DR 1997 Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine and Growth Factor Reviews 8 45-62.
7. Cohen P, Peehl DM, Lamson G & Rosenfeld RG 1991 Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. Journal of Clinical Endocrinology and Metabolism 73 401-407.
8. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR & Rosenfeld RG 1993 Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. Journal of Clinical Endocrinology and Metabolism 76 1031-1035.
9. Colston KW, Mackay AG, James SY, Binderup L, Chander S & Coombes RC 1992 EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochemical Pharmacology 44 2273-2280.
10. Conover CA, Liu F, Powell D, Rosenfeld RG & Hintz RL 1989 Insulin-like growth factor-binding proteins from cultured human fibroblasts. Characterization and hormonal regulation. Journal of Clinical Investigation 83 832-859.
11. Droller MJ 1997 Medical approaches in the management of prostate disease. British Journal of Urology 79 42-52.
12. Feldman D, Skowronski RJ & Peehl DM 1995 Vitamin D and prostate cancer. Advances in experimental Medicine and Biology 375 53-63.
13. Garravvay WM & Alexander FE 1997 Prostate disease: epidemiology, natural history and demographic shifts. British Journal of Urology 79 3-8.
14. Guenette RS & Tenniswood M 1994 The role of growth factors in the suppression of active cell death in the prostate: an hypothesis. Biochemistry and Cell Biology 72 553-559.
15. Hanchette CL & Schwartz GG 1992 Geographic patterns of prostate cancer mortality. Cancer 70 2861-2869.
16. 3 and its analog EB1089. International Journal of Oncology 13 137-143
17. Isaacs JT 1984 Antagonistic effect of androgen on prostatic cell death. Prostate 5 547-557.
18. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B & Karasik A 1993 Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. Journal of Clinical Endocrinology and Metabolism 77 229-233.
19. Konety BR, Schwartz GG, Acierno JS, Becich MJ & Getzenberg RH 1996 The role of vitamin D in normal prostate growth and differentiation. Cell Growth and Differentiation 7 1563-1570.
20. Kyprianou N & Isaacs JT 1988 Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122 552-562.
21. Li M, Liu X, Robinson G, Bar-Peled U, Wagner K-U, Young WS, Hennighausen L & Furth PA 1997 Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution. Proceedings of the National Academy of Sciences of the USA 94 3425-3430.
22. Murphy LJ, Bell GI, Duckworth ML & Friesen HG 1987 Identification, characterization, and regulation of a rat complementary deoxyribonucleic acid which encodes insulin-like growth factor-I. Endocrinology 121 684-691.
23. Nickerson T, Huynh H & Pollak M 1997 Insulin-like growth factor-binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochemical and Biophysical Research Communications 237 690-693.
24. Nickerson T, Pollak M & Huynh H 1998 Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor-binding proteins-2, -3, -4 and -5. Endocrinology 139 807-810.
25. Oh Y, Muller HL, Pham H & Rosenfeld RG 1993 Demonstration of receptors for insulin-like growth factor-binding protein-3 on Hs578T human breast cancer cells. Journal of Biology Chemistry 268 26045-26048.
26. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA & Feldman D 1994 Antiproliferative effects of 1.25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Research 54 805-810.
27. Peehl DM, Cohen P & Rosenfeld RG 1996 Role of insulin-like growth factors in prostate biology. Journal of Andrology 17 2-4.
28. Rajah R, Valentinis B & Cohen P 1997 Insulin-like growth factor-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. Journal of Biological Chemistry 272 12182-12188.
29. Rozen F, Yang X, Huynh HT & Pollak M 1997 Antiproliferative action of vitamin-D-related compounds and insulin-like growth factor-binding protein-5 accumulation. Journal of the Cancer Institute 89 652-656.
30. Schwartz GG & Hulka BS 1990 Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Research 10 1307-1311.
31. Schwartz GG, Oeler TA, Uskokovic MR & Bohnson RR 1994 Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Aniticancer Research 14 1077-1081.
32. 3 and prostate cancer cell proliferation in vivo. Urology 46 365-369.
33. Shimasaki S & Ling N 1991 Identification and molecular characterization of insulin-like growth factor-binding proteins (IGFBP-1,-2,-3,-4,-5 and -6). Progress in Growth Factor Research 3 243-266.
34. Skowronski RJ, Peehl DM & Feldman D 1995 Actions of vitamin D3 analogs on human prostate cancer cell lines: comparison with 1.25-dihydroxyvitamin D3. Endocrinology 136 20-26.
35. Steiner MS 1995 Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. Journal of Urology 153 1085-1096.
36. Tenniswood M 1997 Apoptosis, tumour invasion and prostate cancer. British Journal of Urology 79 27-34.
37. Tonner E, Quarrie L, Travers M, Barber M, Logan A, Wilde C & Flint D 1995 Does an IGF-binding protein (IGFBP) present in involuting rat mammary gland regulate apoptosis? Progress in Growth Factor Research 6 409-414.
38. de Vos S, Holden S, Heber D, Elstner E, Binderup L, Uskokovic M, Rude B, Chen DL, Le J, Cho SK & Koeffler HP 1997 Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines. Prostate 31 77-83.
39. Wang X, Chen X, Akhter J & Morris DL 1997 The in vivo effect of the vitamin D3 analogue EB1089 on a human prostate cancer cell line (PC-3). British Journal of Urology 80 260-262.